Ann: Positive clinical data filed with FDA to support ODD request, page-97

@Bunter62,
While some here are droning on negatively, I think they should ponder your words here #: 72890232 - what really got me excited last year during the MND trial was the announcement that they were observing the suppression of the inflammations associated with MND because research has pointed to MND inflammations as the likely source of the disease. (Of course the apparent stabilisation of the patients' health you point to needs more time before there can be an official announcement (recall that the intention is still for a slowing of MND's progress) but what a prospect !

Here's the summary of the original PharmAust ASX announcement:

4 July 2023

• Motor Neuron Disease Biomarkers and Pharmacodynamics Results• Preliminary data indicate suppression of inflammation that may be responsiblefor MND/ALS progression

https://announcements.asx.com.au/asxpdf/20230704/pdf/05r8yhtvvc5nb1.pdf